Form 4: Cytosorbents Director Bator's New Stock Options

Cytosorbents Corporation Director Michael G. Bator reported the grant of 44,000 stock options and updated his beneficial ownership of common stock and restricted stock units.

Summary

• Michael G. Bator, a Director of Cytosorbents Corp (CTSO), reported changes in his beneficial ownership.
• He was granted 44,000 stock options on August 8, 2025, with an exercise price of $1 per share.
• These options will vest in four equal quarterly installments over one year from the grant date, contingent on his continued service.
• His total beneficial ownership of common stock is 151,273 shares, which includes 81,973 directly owned shares and 69,300 restricted stock units (RSUs).
• The RSUs (3,300 from March 15, 2018; 6,000 from February 24, 2017; 60,000 from June 7, 2016) will vest upon a "Change of Control" of the Company.
• The stock options were granted under the CytoSorbents Corporation 2014 Long-Term Incentive Plan.

Sentiment

Score: 7

Explanation: The filing indicates a routine compensation event for a director, aligning his interests with the company's future performance through stock options. The low exercise price is positive, but the 'Change of Control' vesting for RSUs introduces a minor potential conflict of interest, preventing a higher score.

Positives

• The grant of 44,000 stock options to a director aligns his interests with long-term shareholder value.
• The options have a low exercise price of $1, indicating potential for significant upside if the stock price increases.
• The vesting schedule over one year encourages continued service and commitment from the director.

Negatives

• The vesting of 69,300 restricted stock units is contingent on a "Change of Control," which could incentivize actions leading to a sale of the company rather than long-term independent growth.

Risks

• The "Change of Control" vesting condition for a significant portion of RSUs (69,300 shares) could create a potential conflict of interest, as it might incentivize the director to favor a company sale over other strategic options.

Future Outlook

The grant of stock options with a one-year quarterly vesting schedule indicates an expectation of continued service from Director Michael G. Bator and aligns his incentives with the company's performance over the near to medium term.

Industry Context

This Form 4 filing reflects standard executive compensation practices within the biotechnology or medical device industry, where stock options and restricted stock units are commonly used to incentivize directors and align their interests with shareholder value. The 'Change of Control' clause for RSUs is also a common feature in such compensation plans, designed to provide a payout in the event of an acquisition.

Comparison to Industry Standards

• The use of stock options and restricted stock units for director compensation is a common practice across the biotechnology and medical device sectors, comparable to compensation structures seen at companies like Bio-Rad Laboratories or Thermo Fisher Scientific.
• The exercise price of $1 for the stock options is notably low, which could be a standard practice for certain types of grants or reflect the company's current stock valuation.
• The "Change of Control" vesting for RSUs is a standard provision in many long-term incentive plans, aiming to retain key personnel during acquisition scenarios, similar to clauses found in agreements at companies undergoing M&A activities.

Corporate Governance

Related Party Transactions

• Grant of 44,000 stock options to Director Michael G. Bator as part of his compensation.
• Holding of 69,300 Restricted Stock Units by Director Michael G. Bator, granted as part of his compensation.

Stakeholder Impact

• Shareholders: The grant of stock options aligns the director's interests with shareholder value creation, as the options gain value if the stock price increases. However, the "Change of Control" vesting for RSUs could potentially influence strategic decisions towards a sale.
• Employees: No direct impact mentioned, but the long-term incentive plan framework might be consistent across other employee compensation.

Next Steps

• The 44,000 stock options will vest in four equal quarterly installments over one year following August 8, 2025.
• The 69,300 Restricted Stock Units will vest upon a "Change of Control" of Cytosorbents Corporation.

Key Dates

Recommendation

This Form 4 filing primarily details a routine compensation event for a director, involving the grant of stock options and disclosure of existing equity holdings. While the option grant aligns the director's interests with potential future stock appreciation, it does not provide new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a 'buy' or 'sell' recommendation. The 'Change of Control' vesting for RSUs is a common, albeit sometimes debated, feature in executive compensation. Therefore, based solely on this filing, a 'hold' recommendation is appropriate as it doesn't present a compelling reason to alter an existing investment position.

Keywords

Cytosorbents Corp, CTSO, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Director Compensation, Beneficial Ownership, Executive Compensation, Corporate Governance